Close Menu

Avatao Biotech

NEW YORK (GenomeWeb News) – Rosetta Genomics has terminated a licensing deal with Chinese diagnostic firm Avatao Biotech, the Israeli molecular diagnostic firm disclosed in a document filed with the US Securities and Exchange Commission on Monday.

NEW YORK (GenomeWeb News) – Rosetta Genomics said today it is terminating a licensing deal with Avatao Biotech, accusing the Chinese diagnostic firm of material breach of an agreement.

Rosetta Genomics this week announced that it has signed a definitive agreement to sell $1.9 million in stock and warrants in a private placement.

The Guardian reports that some UK physicians are calling for increased regulation of direct-to-consumer genetic tests.

US tax agency says 23andMe's genetic health test can be claimed as a medical expense for tax purposes, the Wall Street Journal reports.

Two Democratic lawmakers argue at USA Today that independent science is under attack by the Trump Administration.

In PLOS this week: networks of genes co-expressed in depression, role of minichromosome maintenance genes in lung adenocarcinoma, and more.